Immutep and Lonza Sign Agreement
News Apr 11, 2012
Immutep and Lonza have announced an agreement for cell line selection, master cell banking and process development of ImmuFact® IMP321.
Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines.
Immutep announced Phase I/II results for IMP321 in an oral presentation at ASCO (American Society of Clinical Oncology conference) in 2010 describing its use in a chemo-immunotherapy protocol in first-line metastatic breast cancer.
“We are pleased to support Immutep’s development initiatives,” said Janet White, head of Lonza development services.
White continued, “This partnership directly reflects Lonza’s commitment to emerging biotechnology innovation through its clinical milestones.”
IMP321 (LAG-3Ig) has potential for the treatment of advanced cancer in combination with standard first-line chemotherapy.
IMP321 is an antigen presenting cell (APC) activator. Tumour-specific memory CD8 T cells are activated by these APC and contribute to tumour regression.
“We have every confidence in Lonza to carry out the production for pivotal trials and beyond,” said Dr. Frederic Triebel, scientific and medical director of Immutep.
Dr. Triebel continued, “The mechanism of action of this synergistic combination of chemotherapy and active immunotherapy is very simple. The chemotherapy provides a burst of tumour cell debris and the surrounding APC take up the tumour antigens. IMP321 activates these APC resulting in a long-lasting CD8 T cell response against the tumour. We think that the combination of first-line standard chemotherapy plus IMP321 should be tested in several first-line indications. We are in partnering discussions at present.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018